Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 1;35(1):6-14.
doi: 10.1097/GCO.0000000000000838. Epub 2022 Dec 8.

Advances in antibody-drug conjugates for gynecologic malignancies

Joan Tymon-Rosario  1 , Megan Gorman  1 , Debra L Richardson  2 , Christina Washington  2 , Alessandro D Santin  3
Affiliations
Review

Advances in antibody-drug conjugates for gynecologic malignancies

Joan Tymon-Rosario et al. Curr Opin Obstet Gynecol. .

Abstract

Purpose of review: Antibody-drug conjugates (ADCs) represent a new class of drugs that combine a surface receptor-targeting antibody linked to a cytotoxic molecule delivering the potent cytotoxic payload directly to tumor cells. This review summarizes the current literature demonstrating their use in the treatment of gynecologic malignancies.

Recent findings: Tisotumab vedotin is the first U.S. Food and Drug Administration (FDA) approved ADC for the treatment of gynecologic cancers. While in the phase 3 randomized controlled trial in platinum resistant ovarian cancer patients, FORWARD 1, mirvetuximab did not meet its primary endpoint of progression-free survival. But we await more recent data from the two ongoing phase 3 trials of mirvetuximab in recurrent ovarian cancer patients. HER2/neu, Napi2b, mesothelin, and human trophoblast cell-surface marker (Trop-2) overexpression have also been exploited as excellent targets by novel ADCs in multiple tumors including ovarian, endometrial, and cervical cancers.

Summary: Current evidence strongly supports the use of ADCs and ongoing clinical trials will provide further information into the potential of making these drugs part of current standard practice allowing patients to be treated with a higher level of personalized cancer care.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-...
    1. U.S. Food & Drug Administration. FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer [Internet]. FDA: 2021 Sep 21. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grant...
    1. Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021; 22:609–619.
    1. Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci USA 2013; 110:2916–2921.
    1. Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 2013; 26:1605–1612.

Publication types

MeSH terms